Figure 3 | British Journal of Cancer

Figure 3

From: Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer

Figure 3

Survival curves by the change of serum levels of ligands after treatment. Survival curves of PFS by pretreatment levels of HGF and EREG (high/low) and change of serum levels at PD compared with pretreatment (elevation/no elevation) levels are shown. (A) PFS curves divided by change of serum HGF levels. (B) PFS curves divided by change of serum EREG levels. (C) OS curves divided by change of serum HGF levels. (D) OS curves divided by change of serum EREG levels.

Back to article page